F8 and hemophilia A: Given that patients typically have polyclonal responses to fVIII, epitope mapping of patient plasmas to these sites could help determine the response to fVIII supplementation on top of rfVIIa therapy and may provide a novel approach towards the treatment of hemophilia A complicated by anti-fVIII inhibitors.